Literature DB >> 11466683

A prospective study of factors predicting clinically occult spinal cord compression in patients with metastatic prostate carcinoma.

A Bayley1, M Milosevic, R Blend, J Logue, M Gospodarowicz, I Boxen, P Warde, M McLean, C Catton, P Catton.   

Abstract

BACKGROUND: The objective of this study was to identify clinical parameters that predict occult subarachnoid space or spinal cord (SAS/SC) compression, as determined by magnetic resonance imaging (MRI), in patients with metastatic prostate carcinoma.
METHODS: A prospective study was performed in which 68 patients with bone metastases from prostate carcinoma and a normal neurologic examination underwent MRI of the entire spine after documentation of clinical, X-ray, and bone scan parameters potentially predictive of occult SAS/SC compression.
RESULTS: Occult SAS/SC compression was diagnosed in 22 patients (32%) using MRI. Nine patients (13%) had compressions at two discontinuous spinal levels. Extensive disease on bone scan, the duration of continuous hormonal therapy prior to study entry, and hemoglobin concentration were found to predict SAS/SC compression by univariate analysis. The extent of disease on bone scan and the duration of continuous hormonal therapy were independent predictors of SAS/SC compression by multivariate analysis (P = 0.02 and P = 0.04, respectively). The risk of occult SAS/SC compression increased from 32% to 44% in patients with a bone scan that showed > 20 metastases as the duration on hormones increased from 0 to 24 months. The risk in patients with fewer metastases increased from 11% to 17% over the same interval. The presence or absence of back pain was not predictive of SAS/SC compression.
CONCLUSIONS: Patients who are at high risk for occult SAS/SC compression can be identified using clinical parameters and readily available diagnostic tests. These high-risk patients should undergo MRI screening with the aim of diagnosing and treating spinal cord compression before the development of neurologic deficits that may be irreversible. Copyright 2001 American Cancer Society.

Entities:  

Mesh:

Year:  2001        PMID: 11466683     DOI: 10.1002/1097-0142(20010715)92:2<303::aid-cncr1323>3.0.co;2-f

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  12 in total

1.  The Metastatic Spine Disease Multidisciplinary Working Group Algorithms.

Authors:  Adam N Wallace; Clifford G Robinson; Jeffrey Meyer; Nam D Tran; Afshin Gangi; Matthew R Callstrom; Samuel T Chao; Brian A Van Tine; Jonathan M Morris; Brian M Bruel; Jeremiah Long; Robert D Timmerman; Jacob M Buchowski; Jack W Jennings
Journal:  Oncologist       Date:  2015-09-09

Review 2.  Clinical outcome of metastatic spinal cord compression treated with surgical excision ± radiation versus radiation therapy alone: a systematic review of literature.

Authors:  Jaehon M Kim; Elena Losina; Christopher M Bono; Andrew J Schoenfeld; Jamie E Collins; Jeffrey N Katz; Mitchel B Harris
Journal:  Spine (Phila Pa 1976)       Date:  2012-01-01       Impact factor: 3.468

3.  Predictors of skeletal complications in men with hormone-refractory metastatic prostate cancer.

Authors:  Matthew R Smith; Richard J Cook; Robert Coleman; Janet Brown; Allan Lipton; Pierre Major; Yong Jiang Hei; Fred Saad
Journal:  Urology       Date:  2007-08       Impact factor: 2.649

Review 4.  Radiotherapeutic approaches to metastatic disease.

Authors:  Edward Chow; Jackson Wu; Andrew Loblaw; Carlos A Perez
Journal:  World J Urol       Date:  2003-08-09       Impact factor: 4.226

5.  Radiographic Local Control of Spinal Metastases with Percutaneous Radiofrequency Ablation and Vertebral Augmentation.

Authors:  A N Wallace; A Tomasian; D Vaswani; R Vyhmeister; R O Chang; J W Jennings
Journal:  AJNR Am J Neuroradiol       Date:  2015-12-03       Impact factor: 3.825

6.  Radiotherapy for oligometastases and oligo-recurrence of bone in prostate cancer.

Authors:  Ken-Ichi Tabata; Yuzuru Niibe; Takefumi Satoh; Hideyasu Tsumura; Masaomi Ikeda; Satoru Minamida; Tetsuo Fujita; Daisuke Ishii; Masatsugu Iwamura; Kazushige Hayakawa; Shiro Baba
Journal:  Pulm Med       Date:  2012-09-09

7.  Pathologic fracture and metastatic spinal cord compression in patients with prostate cancer and bone metastases.

Authors:  Carsten Nieder; Ellinor Haukland; Adam Pawinski; Astrid Dalhaug
Journal:  BMC Urol       Date:  2010-12-22       Impact factor: 2.264

8.  A systematic and evidence-based approach to the management of vertebral metastasis.

Authors:  Richard L S Jennelle; Vani Vijayakumar; Srinivasan Vijayakumar
Journal:  ISRN Surg       Date:  2011-08-02

9.  Predictive factors for skeletal complications in hormone-refractory prostate cancer patients with metastatic bone disease.

Authors:  A Berruti; M Tucci; A Mosca; R Tarabuzzi; G Gorzegno; C Terrone; F Vana; G Lamanna; M Tampellini; F Porpiglia; A Angeli; R M Scarpa; L Dogliotti
Journal:  Br J Cancer       Date:  2005-09-19       Impact factor: 7.640

10.  Management of patients with advanced prostate cancer: recommendations of the St Gallen Advanced Prostate Cancer Consensus Conference (APCCC) 2015.

Authors:  S Gillessen; A Omlin; G Attard; J S de Bono; E Efstathiou; K Fizazi; S Halabi; P S Nelson; O Sartor; M R Smith; H R Soule; H Akaza; T M Beer; H Beltran; A M Chinnaiyan; G Daugaard; I D Davis; M De Santis; C G Drake; R A Eeles; S Fanti; M E Gleave; A Heidenreich; M Hussain; N D James; F E Lecouvet; C J Logothetis; K Mastris; S Nilsson; W K Oh; D Olmos; A R Padhani; C Parker; M A Rubin; J A Schalken; H I Scher; A Sella; N D Shore; E J Small; C N Sternberg; H Suzuki; C J Sweeney; I F Tannock; B Tombal
Journal:  Ann Oncol       Date:  2015-06-03       Impact factor: 32.976

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.